CBLI
Cytocom, Inc.
Set alert
52-week range unavailable
- Open
- 3.44
- Prev close
- 3.17
- Mkt cap
- 107.66M
- Vol
- 116.25K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.11
- High
- 3.50
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.08
- Inst. own
- 4.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 16, 2021
- 50-d avg
- 3.62
- 200-d avg
- 3.62
- 1y target
- 0.00
Key statistics
- Market cap
- 107.66M
- Enterprise value
- 79.97M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.742
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 151.91K
- Total debt
- 2.00M
- Return on equity
- 0.00%
- Shares outstanding
- 33.96M
- Short % of float
- 0.00%
- 50-day average
- 3.62
- 200-day average
- 3.62
Analyst view
Consensus: none
Next earnings
Aug 16, 2021
Expected Aug 16, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 16, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
| May 15, 2020 | Mar 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 24, 2014 | Cantor Fitzgerald | down | Buy | Hold |
| Mar 21, 2013 | Cantor Fitzgerald | init | — | Buy |
| Mar 20, 2013 | Cantor Fitzgerald | init | — | Buy |
| Dec 6, 2012 | Oppenheimer | init | — | Outperform |
| Dec 4, 2012 | Burrill & Company | init | — | Market Outperform |
About Cytocom, Inc.
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytocom.com
News
- Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
- Cytocom, Inc. Reports Second Quarter 2021 Financial Results
- Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
- Cytocom, Inc. to Report Second Quarter 2021 Financial Results
- Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
- Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
- Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
- Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
- CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
- Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
Your note
Sign in to keep a note on CBLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARONSTAM PETER | Chief Financial Officer | Stock Award(Grant) | Jul 26, 2021 | 141,370 |
| BROWN JULIA R | Director | Stock Award(Grant) | Jan 7, 2015 | 116,482 |
| BUCKHEIT ROBERT | Chief Technology Officer | Stock Award(Grant) | Jul 26, 2021 | 24,378 |
| DICORLETO PAUL E | Director | Stock Award(Grant) | Jun 18, 2013 | 41,968 |
| HOHN DAVID C | Director | Stock Award(Grant) | Mar 12, 2014 | 43,049 |
| MCAVOY COZETTE M | Officer | Stock Award(Grant) | Jul 26, 2021 | 60,947 |